Beta Bionics, Inc. (BBNX) Presents at Morgan Stanley 23rd Annual Global Healthcare

Stephen Feider
CFO, Treasurer & Secretary

I’m Stephen, and this is Sean.

Patrick Wood
MD of Equity Research

Welcome. Disclosures. You’re not going to go to the website anyway, but it’s here if you feel really compelled. Massive, thank you to Stephen and Sean for coming along from Beta Bionics and agreeing to this, and I really appreciate having you guys.

Stephen Feider
CFO, Treasurer & Secretary

Thanks, Patrick. Great to be here.

Sean Saint
President, CEO & Director

Yes. It’s been a good conference — and yes, we’re looking forward to the time here.

Patrick Wood
MD of Equity Research

Yes, good energy. I mean let’s just dive into right — like why don’t we — I mean maybe 2 minutes just to level set people. I think probably almost everybody in this room is aware of like pumps and how that market works. But maybe just from your perspective, what really distinguishes beta relative to the pump competitors?

Sean Saint
President, CEO & Director

Yes, absolutely. So we all know Beta Bionics is an automated insulin delivery pump, but we don’t like to call it an insulin pump, let’s call it bionic pancreas to differentiate it, why the difference? It is the most automated version of an insulin delivery system ever. We’ve all been adding these user simplicity functions like trying to reduce boluses and whatnot, and we’ve done that completely.

But we’ve also added the concept of moving from a static to an adaptive algorithm, which removes the need for the health care provider